N. Stoehr

发表

(−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection

I. Vranesic, G. Battaglia, M. Maj, 2003, Neuropharmacology.

CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.

F. Gasparini, L. Prézeau, I. Vranesic, 1999, Molecular pharmacology.

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist

Roland Heckendorn, Hans Allgeier, Fabrizio Gasparini, 1999, Neuropharmacology.

Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino- 1a, 2-dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-carboxylic acid ethyl ester.

F. Gasparini, E. Francotte, P. Flor, 2000, Journal of medicinal chemistry.

The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors*

F. Gasparini, L. Prézeau, I. Vranesic, 2000, The Journal of Biological Chemistry.

[(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5.

Fabrizio Gasparini, K. Lingenhöhl, F. Gasparini, 2002, Bioorganic & medicinal chemistry letters.

Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain

W. Spooren, F. Gasparini, I. Vranesic, 2001, Neuropharmacology.

Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors.

F. Gasparini, I. Vranesic, P. Flor, 2001, Farmaco.

Atg4b-Dependent Autophagic Flux Alleviates Huntington’s Disease Progression

T. Bouwmeester, C. Genoud, Ivan Galimberti, 2013, PloS one.

A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo.

J. Cryan, O. Pescott, P. Flor, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Assessment of neuronal cell type specific transcriptional effects of three pathological sequence variants of the FMR1 gene promoter

Ivan Galimberti, B. Fodor, N. Stoehr, 2014 .

CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency

Jeffrey A. Porter, R. Dolmetsch, T. Bouwmeester, 2016, Science.

In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: Review article

F. Gasparini, K. Lingenhöhl, W. Spooren, 2002, Amino Acids.

Selective MALT1 paracaspase inhibition does not block TNF-α production downstream of TLR4 in myeloid cells.

N. Stoehr, C. Farady, F. Bornancin, 2017, Immunology letters.